UMIN ID: UMIN000011549
Registered date:01/09/2013
Rituxan injection specific drug use-results survey
Basic Information
| Recruitment status | Complete: follow-up complete |
|---|---|
| Health condition(s) or Problem(s) studied | Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA) |
| Date of first enrollment | 2013/10/01 |
| Target sample size | |
| Countries of recruitment | Japan |
| Study type | Observational |
| Intervention(s) |
Outcome(s)
| Primary Outcome | 1. Safety (infusion-related reactions and infections) 2. Efficacy |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | Not applicable |
|---|---|
| Age maximum | Not applicable |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | None |
Related Information
| Primary Sponsor | Zenyaku Kogyo Co., Ltd. |
|---|---|
| Secondary Sponsor | Chugai Pharmaceutical Co., Ltd. |
| Source(s) of Monetary Support | Zenyaku Kogyo Co., Ltd. |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Takashi Ando |
| Address | 6-15, Otsuka 5-chome, Bunkyo-ku, Tokyo 112-8650, Japan Japan |
| Telephone | 03-3946-1136 |
| Takashi_Ando@mail.zenyaku.co.jp | |
| Affiliation | Zenyaku Kogyo Co., Ltd. Pharmacovigilance Department |
| scientific contact | |
| Name | Kenichiro Inatomi |
| Address | 6-15, Otsuka 5-chome, Bunkyo-ku, Tokyo 112-8650, Japan Japan |
| Telephone | 03-3946-1136 |
| Kenichiro_Inatomi@mail.zenyaku.co.jp | |
| Affiliation | Zenyaku Kogyo Co., Ltd. Pharmacovigilance Department |